Navigation Links
Mechanical ventilation for patients with lung damage don't always work as planned
Date:11/12/2009

TORONTO, Ont., November 12, 2009 As more Canadians are diagnosed with H1N1 influenza infection, some will be admitted to hospital. The most severely affected may be treated in the intensive care unit (ICU) and placed on a mechanical ventilator to help them breathe while they recover from the infection.

While mechanical ventilation clearly saves the lives of many people felled by serious illness, in some cases, this supportive measure has been known to damage the lungs, says Dr. Arthur S. Slutsky, a scientist at St. Michael's Hospital in Toronto.

"In clinicians' previous zeal to maintain relatively normal blood gas values, they have ventilated patients using relatively large tidal volumes," Dr. Slutsky explains. "They also tended to ventilate patients in the supine positionthat is, while they lay on their backs."

("Tidal volume" refers to the normal volume of air displaced in the lungs between normal inhalation and exhalation when extra effort is not applied. Other studies have found that lowering tidal volumes decreases mortality rates in ventilated patients.)

"Ventilation is what we call a physiological-based treatment," he explains. "We look at the patient's current physiological state, then devise and use treatments aimed at altering this state, hoping the change will translate into recovery."

In the case of severe H1N1 infection of the lungs, patients can develop severe hypoxemiaan abnormally low amount of oxygen in the arterial blood which is the major result of respiratory failure.

In an editorial published this week in the Journal of the American Medical Association (JAMA), Dr. Slutsky comments on new research published by Fabio S. Taccone and colleagues from the University of Milan in Milan, Italy.

The researchers looked at whether patients with Acute Respiratory Distress Syndrome (ARDS) who were mechanically ventilated in the prone position (lying on their stomachs) did better than patients ventilated while they were supine (lying on their backs), as is the standard approach. As in other studies of this physiological-based treatment, blood oxygen levels increased in the prone treatment group. But in the end, the mortality rate among these patients was not statistically different from that of the control group.

In his editorial, Dr. Slutsky asks the following question: "Today, 35 years after prone ventilation was suggested and after hundreds of articles have been published, including more than 150 review articles and more than 10 meta-analyses, why are more definitive conclusions about prone ventilation not available?"

Unfortunately, he says, very few large companies have a commercial interest in this type of interventionfor example, changing a ventilated patient from a supine to a prone position. This explains why funding for such research is hard to obtain and why clear answers about the usefulness of physiological interventions are often lacking.

In this regard, prone ventilation is similar to other physiologically-based interventions for which the effect on important clinical outcomes has not been conclusively proven. In some cases, these physiological "fixes" do not always work as plannedinterventions that improve one physiological value may actually worsen another.

In his editorial, Dr. Slutsky says that basing treatments strictly on physiological endpointsin this case, increasing oxygenation in the blood by mechanically increasing volumes of air in the lungs and changing patients' position during treatmentis "seductive" for several reasons:

  • In many ways, the intensive care unit is a physiology laboratory in which patients' vital signs and other functions are monitored and treated around the clock, seven days a week. By explaining why a patient has a physiological abnormality such as a decrease in oxygenation or worsening kidney function, these measurements can suggest therapies to correct the abnormal physiology.

  • Many physiological interventions can be quickly instituted and monitored at the bedside. They are usually relatively inexpensive or seen as "free," which makes them attractive and easy to implement.

"But while physiological insights developed at the bedside have led to important, lifesaving therapies, it's been difficult to obtain convincing proof of better clinical outcomes for many such interventions," Dr. Slutsky says.

One solution would be to design large, simple, generalizable trials undertaken by a large global network of investigators. "The time for this may be especially opportune because the world's critical care community is coalescing around an initiative to perform large-scale clinical trials to rapidly address the potential H1N1 pandemic," he says, adding that such trials are necessary to "separate fact from seduction."


'/>"/>

Contact: Julie Saccone
sacconej@smh.toronto.on.ca
416-864-5047
St. Michael's Hospital
Source:Eurekalert

Related medicine news :

1. ATS Medical Receives FDA Approval for AP360 Mechanical Heart Valve
2. New research for mechanical support devices in pediatrics to be released at ISHLT
3. FDA approves HeartMate II mechanical heart pump for heart-failure patients
4. Physical therapists test mechanical arm to help patients recover from stroke, traumatic brain injury
5. ATS Medical Announces Regulatory Approval of the ATS Open Pivot AP360 Mechanical Heart Valve in Japan
6. First heart patients implanted with next-generation mechanical heart pump
7. Pharmacomechanical Thrombectomy Procedure Adoption to Accelerate Due to More Aggressive Treatment of Deep Vein Thrombosis, According to Millennium Research Group
8. Reportlinker Adds Mechanical Ventilators Report
9. Data Show Long-Term Mechanical Integrity of MitraClip(R) and Complete Healing Following Implantation of the Device for Mitral Valve Repair
10. Improved robotic hand captures mechanical engineering top award
11. Measures to assess potential lung injury during ventilation inadequate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2016)... ... May 23, 2016 , ... While new U.S. opioid ... physicians are not legally required to follow them. In the absence of federal ... Novus Medical Detox Center , a leading Florida-based drug treatment facility, strongly ...
(Date:5/23/2016)... ... ... the upcoming airing of Innovations with Ed Begley, Jr., ... 4:00pET via Fox Business. , The show will explore ... safely and rapidly develop cures for mosquito-borne, emerging infectious ...
(Date:5/23/2016)... , ... May 23, 2016 ... ... Size for Verification and Validation:, Tools to Safely Speed Your Device to ... http://www.fdanews.com/bestdevicesamplesizevv                  , Today's FDA inspectors focus like lasers on device ...
(Date:5/23/2016)... (PRWEB) , ... May 23, 2016 , ... ... the action analytics leader as Chief Medical Officer. Dr. O’Connor’s deep expertise in ... product development and client services teams who deliver best-in-class solutions and transformative technologies ...
(Date:5/23/2016)... Valley, California (PRWEB) , ... May 23, 2016 ... ... clinical communications and solutions for healthcare providers announced today that AGNITY MobileCare™ Platform ... and health collaboration applications as a part of its M-Health Solution. Tech Mahindra ...
Breaking Medicine News(10 mins):
(Date:5/19/2016)... Israel , May 19, 2016 ... the "Company"), an emerging global ophthalmic company focused on ... candidates which address ophthalmic conditions, announced today that it ... Italy ) for the manufacturing, distribution, marketing ... for the treatment of dry eye syndrome (DES) and ...
(Date:5/19/2016)... May 19, 2016 A ... World Biopsy Devices Market Opportunities and Forecasts, 2014 ... market generated $1,621 million in 2015. The MRI-guided ... and is expected to maintain this trend over ... http://photos.prnewswire.com/prnh/20140911/647229 ) , To know ...
(Date:5/19/2016)... BioLineRx Ltd. (NASDAQ/TASE: BLRX) announced ... of multiple cancer and hematological indications, will be presented ... titled " Clinical response in relapsed/refractory AML patients correlates ... a potent CXCR4 antagonist; results of a Phase 2a ... the European Hematology Association 21st Congress, to be held ...
Breaking Medicine Technology: